Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7

Neurology

Volumn 74, Issue 19, 2010, Pages 1517-1523

  Lashley, D ^a,b   Palace, J ^b   Jayawant, S ^c   Robb, S ^d   Beeson, D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Boston University Medical Campus   (United States)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPHEDRINE; PROTEIN; PROTEIN DOK 7; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONGENITAL MYASTHENIC SYNDROME; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; EXTRAOCULAR MUSCLE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GENE MUTATION; HUMAN; MALE; MUSCLE FUNCTION; MUSCLE STRENGTH; MYASTHENIA GRAVIS; NEWBORN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM;

COHORT STUDIES; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPHEDRINE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; MUSCLE PROTEINS; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUTATION; MYASTHENIC SYNDROMES, CONGENITAL; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; SYMPATHOMIMETICS; TREATMENT OUTCOME;

EID: 77952144985     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181dd43bf     Document Type: Article

References (28)

1. Engel AG, Shen XM, Selcen D, Sine SM. What have we learned from the congenital myasthenic syndromes? J Mol Neurosci Epub 2009.
2. Palace J, Beeson D. The congenital myasthenic syndromes. J Neuroimmunol 2008;201-202:2-5.
3. Beeson D, Higuchi O, Palace J, et al. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 2006;313:1975-1978.
4. Muller J, Herczegfalvi A, Vilchez J, et al. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain 2007;130:1497-1506.
5. Palace J, Lashley D, Newsom-Davis J, et al. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain 2007;130:1507-1515.
6. Selcen D, Milone M, Shen XM, et al. Dok-7 myasthenia: phenotypic and molecular genetic studies in 16 patients. Ann Neurol 2008;64:71-87.
7. Anderson J, Ng J, Bowe C, et al. Variable phenotypes associated with mutations in DOK7. Muscle Nerve 2008;37: 448-456.
8. Okada K, Inoue A, Okada M, et al. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 2006;312:1802-1805.
9. Vogt J, Morgan NV, Marton T, et al. Germline mutation in DOK7 associated with fetal akinesia deformation sequence. J Med Genet 2009;46:338-340.
10. Slater CR, Fawcett PR, Walls TJ, et al. Pre-and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia.' Brain 2006;129:2061-2076.
11. Edgeworth H. A report of progress on the use of ephedrine in a case of myasthenia gravis. JAMA 1930;94:1136.
12. Edgeworth H. The effect of ephedrine in the treatment of myasthenia gravis. JAMA 1933;100:1401.
13. Wood SJ, Slater CR. Safety factor at the neuromuscular junction. Prog Neurobiol 2001;64:393-429.
14. Sieb J, Engel AG. Ephedrine: effects on neuromuscular transmission. Brain Res 1993;623:167-171.
15. Milone M, Engel AG. Block of endplate acetylcholine receptor channel by the sympathomimetic agents ephedrine, pseudoephedrine and albuterol. Brain Res 1996;18:346-352.
16. Engel AG. The therapy of congenital myasthenic syndromes. Neurotherapeutics 2007;4:186-197.
17. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards: Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
18. Lynch GS, Ryall JG. Role of/3-adrenoreceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 2008;88:729-767.
19. Kinali M, Beeson D, Pitt MC, et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. J Neuroimmunol 2008;201-202:6-12.
20. Bestue-Cardiel M, Saenz de Cabezon-Alvarez A, Capablo-Liesa JL, et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 2005;65:144-146.
21. Mihaylova V, Muller JS, Vilchez JJ, et al. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain 2008;131:747-759.
22. Huze C, Bauche S, Richard P, et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 2009;85:155-167.
23. Finn AJ, Feng G, Pendergast AM. Postsynaptic requirement for Abl kinases in assembly of the neuromuscular junction. Nat Neurosci 2003;6:717-723.
24. Burden SJ, Fuhrer C, Hubbard SR. Agrin/MuSK signaling: willing and Abl. Nat Neurosci 2003;6:653-654.
25. Wiesner A, Fuhrer C. Regulation of nicotinic acetylcholine receptors by tyrosine kinases in the peripheral and central nervous system: same players, different roles. Cell Mol Life Sci 2006;63:2818-2828.
26. Hamuro J, Higuchi O, Okada K, et al. Mutations causing DOK7 congenital myasthenia ablate functional motifs in Dok-7. J Biol Chem 2008;283:5518-5524.
27. Yamanashi Y, Higuchi O, Beeson D. Dok7/MuSK signaling and a congenital myasthenic syndrome. Acta Myo-logica 2008;27:25-29.
28. Schara U, Barisic N, Deschauer M, et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord 2009;19: 828-832.